Peptide Retatrutide 5mg/vial 10mg/vial
investigación- Descripción
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known.
Methods
We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) de 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 semanas. The primary end point was the percentage change in body weight from baseline to 24 semanas. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% o más, 10% o más, or 15% o más. Safety was also assessed.
Conclusions
In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.
Péptidos tirzepatide cost, tirzepatide online, tirzepatide injections, mounjaro 5mg, tirzepatide for weight loss, mounjaro injection, Retatrutide, Tirzepatide, tirzepatide weight loss, mounjaro
ENVIAR CONSULTA
Productos relacionados
© rawsteroidpowder.com 2024. Reservados todos los derechos
Desarrollado por wpboss
Servicio
Telegrama：Anabolicraws
Signal:Anabolicraws.11
